MX2016016383A - Derivados de indolin-2-ona o pirrolo-piridin-2-ona. - Google Patents
Derivados de indolin-2-ona o pirrolo-piridin-2-ona.Info
- Publication number
- MX2016016383A MX2016016383A MX2016016383A MX2016016383A MX2016016383A MX 2016016383 A MX2016016383 A MX 2016016383A MX 2016016383 A MX2016016383 A MX 2016016383A MX 2016016383 A MX2016016383 A MX 2016016383A MX 2016016383 A MX2016016383 A MX 2016016383A
- Authority
- MX
- Mexico
- Prior art keywords
- lower alkyl
- disease
- alkyl substituted
- heteroaryl group
- halogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Transplantation (AREA)
Abstract
La presente invención se refiere a 2-oxo-2,3-dihidro-indoles de fórmula general: en la que: Ar1 es fenilo o un grupo heteroarilo de cinco o seis elementos, que contiene uno, dos o tres heteroátomos seleccionados de entre N, S o O, caracterizado porque el heteroátomo N en el grupo heteroarilo puede oxidarse a N+-(O-), R1 es alquilo inferior, halógeno, ciano o cicloalquilo, Ar2 es un grupo heteroarilo de cinco o seis elementos, que contiene uno, dos, tres o cuatro heteroátomos, seleccionados de entre N, S o O, en donde el heteroátomo N en el grupo heteroarilo puede oxidarse a N+-(O-), o es benzo[b]tiofenilo, R2 es hidrógeno, alquilo inferior, halógeno, ciano, alquilo inferior sustituido con hidroxilo, alquilo inferior sustituido con halógeno, alquilo inferior sustituido con amino, alquilo inferior sustituido con alcoxi, alquilo inferior sustituido con amida, o es cicloalquilo, X es CH o N, n es 1 ó 2, m es 1 ó 2, así como a una sal farmacéuticamente aceptables de los mismos, con una mezcla racémica, o con su enantiómero y/o isómero óptico y/o estereoisómero correspondiente. Los compuestos pueden usarse en el tratamiento de enfermedades del SCN relacionadas con síntomas positivos (psicosis) y negativos de la esquizofrenia, abuso de sustancias, adicción al alcohol y drogas, trastornos obsesivo-compulsivos, alteraciones cognitivas, trastornos bipolares, trastornos del humor, depresión mayor, depresión resistente al tratamiento, trastornos de ansiedad, enfermedad de Alzheimer, autismo, enfermedad de Parkinson, dolor crónico, trastorno límite de la personalidad, enfermedades neurodegenerativas, alteraciones del sueño, síndrome de fatiga crónica, rigidez, enfermedades inflamatorias, asma, enfermedad de Huntington, ADHD, esclerosis lateral amiotrófica, epilepsia, efectos en la artritis, enfermedades autoinmunitarias, infecciones víricas y fúngicas, enfermedades cardiovasculares, enfermedades oftalmológicas e inflamatorias retinianas y problemas del equilibrio.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14174559 | 2014-06-26 | ||
| PCT/EP2015/064016 WO2015197567A1 (en) | 2014-06-26 | 2015-06-23 | Indolin-2-one or pyrrolo-pyridin-2-one derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016016383A true MX2016016383A (es) | 2017-05-01 |
Family
ID=50981417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016016383A MX2016016383A (es) | 2014-06-26 | 2015-06-23 | Derivados de indolin-2-ona o pirrolo-piridin-2-ona. |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US20170101409A1 (es) |
| EP (1) | EP3160957B1 (es) |
| JP (1) | JP6442537B2 (es) |
| KR (1) | KR101819433B1 (es) |
| CN (1) | CN106459029B (es) |
| AR (1) | AR100979A1 (es) |
| AU (1) | AU2015279377B2 (es) |
| BR (1) | BR112016026596A2 (es) |
| CA (1) | CA2950475C (es) |
| CL (1) | CL2016003212A1 (es) |
| CR (1) | CR20160578A (es) |
| EA (1) | EA033420B1 (es) |
| IL (1) | IL248550B (es) |
| MX (1) | MX2016016383A (es) |
| MY (1) | MY186124A (es) |
| PE (1) | PE20161476A1 (es) |
| PH (1) | PH12016502231B1 (es) |
| SG (1) | SG11201610740QA (es) |
| TW (1) | TWI659025B (es) |
| UA (1) | UA119175C2 (es) |
| WO (1) | WO2015197567A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108349942B (zh) | 2015-11-06 | 2021-03-30 | 豪夫迈·罗氏有限公司 | 用于治疗cns和相关疾病的二氢吲哚-2-酮衍生物 |
| MY197370A (en) | 2015-11-06 | 2023-06-14 | Hoffmann La Roche | Indolin-2-one derivatives |
| JP6839184B2 (ja) | 2015-11-06 | 2021-03-03 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | インドリン−２−オン誘導体 |
| WO2017076932A1 (en) * | 2015-11-06 | 2017-05-11 | F. Hoffmann-La Roche Ag | Indolin-2-one derivatives useful in the treatment of cns diseases |
| US11261188B2 (en) | 2016-11-28 | 2022-03-01 | Praxis Precision Medicines, Inc. | Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel |
| BR112019010880A2 (pt) | 2016-11-28 | 2019-10-01 | Praxis Prec Medicines Inc | compostos e seus métodos de uso |
| WO2018148745A1 (en) * | 2017-02-13 | 2018-08-16 | Praxis Precision Medicines , Inc. | Compounds and their methods of use |
| US11731966B2 (en) | 2017-04-04 | 2023-08-22 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| WO2019035951A1 (en) | 2017-08-15 | 2019-02-21 | Praxis Precision Medicines, Inc. | COMPOUNDS AND THEIR METHODS OF USE |
| CN109942581B (zh) * | 2017-12-21 | 2020-09-04 | 武汉尚赛光电科技有限公司 | 二氢吲哚[3,2-a]咔唑与吡啶类衍生物及其制备方法、应用和器件 |
| AU2019278814A1 (en) | 2018-05-30 | 2020-12-17 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| US11773099B2 (en) | 2019-05-28 | 2023-10-03 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11279700B2 (en) | 2019-05-31 | 2022-03-22 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
| CA3152752A1 (en) | 2019-10-01 | 2021-04-08 | Thomas Henley | Genetic engineering of fungi to modulate tryptamine expression |
| US11767325B2 (en) | 2019-11-26 | 2023-09-26 | Praxis Precision Medicines, Inc. | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3935514A1 (de) | 1989-10-25 | 1991-05-02 | Boehringer Mannheim Gmbh | Neue bicyclo-imidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| DE4427648A1 (de) * | 1994-08-04 | 1996-02-08 | Basf Ag | N-Stubstituierte 3-Azabicyclo[3,2,0,]heptan-Derivate, ihre Herstellung und Verwendung |
| CA2294011A1 (en) | 1997-06-16 | 1998-12-23 | Janssen Pharmaceutica N.V. | Use of draflazine-analogues for treating pain |
| IT1318403B1 (it) | 2000-03-17 | 2003-08-25 | Cooperativa Ct Ricerche Poly T | Esteri polisaccaridici di n-derivati di acido glutammico. |
| DE60115656T2 (de) * | 2000-06-29 | 2006-06-14 | Neurosearch As | Verwendung von 3-substituierten oxidinolderivaten als kcnq kaliumkanalmodulatoren |
| US6524302B2 (en) | 2001-04-26 | 2003-02-25 | Scimed Life Systems, Inc. | Multi-lumen catheter |
| WO2004060902A2 (en) | 2002-12-31 | 2004-07-22 | John K Buolamwini | Novel nucleoside transport inhibitors |
| US7183305B2 (en) | 2003-11-11 | 2007-02-27 | Allergan, Inc. | Process for the synthesis of imidazoles |
| ES2294400T3 (es) | 2004-06-29 | 2008-04-01 | Grunenthal Gmbh | Nuevos analogos de notrobenciltioinosina. |
| US20060253263A1 (en) | 2005-04-11 | 2006-11-09 | Meshkin Brian J | Method to optimize drug selection, dosing and evaluation and to help predict therapeutic response and toxicity from immunosuppressant therapy |
| AR056317A1 (es) * | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
| EP1993540A4 (en) | 2006-03-07 | 2010-06-09 | Combinatorx Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS |
| MX2008016083A (es) * | 2006-06-26 | 2009-03-20 | Helicon Therapeutics Inc | Metodo para modular la excrecion de neuritas por el uso de un antagonista del receptor de galanina-3. |
| WO2008046083A2 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Use of oxindole compounds as therapeutic agents |
| US20100284984A1 (en) | 2007-07-30 | 2010-11-11 | University Of Rochester | Adenosine and its mimetics. modulators, transport inhibitors, and receptor agonists as a therapeutic tool to replace or improve the efficacy of deep brain stimulation |
| JO3126B1 (ar) | 2007-11-14 | 2017-09-20 | Janssen Pharmaceutica Nv | مثبطات ناقل نيوكليوسيد متوازن اي ان تي 1 |
| JP5584132B2 (ja) | 2007-11-15 | 2014-09-03 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 疼痛の治療のための前立腺酸性ホスファターゼ |
| EP2108641A1 (en) * | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
| EP2113503A1 (en) * | 2008-04-28 | 2009-11-04 | Laboratorios Almirall, S.A. | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors |
| CN102316738A (zh) | 2009-02-18 | 2012-01-11 | 盛泰萨路申有限公司 | 作为激酶抑制剂的酰胺类 |
| GB201106817D0 (en) | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compound |
| CN104619701B (zh) * | 2012-09-13 | 2016-10-19 | 霍夫曼-拉罗奇有限公司 | 用于治疗cns疾病的2-氧代-2，3-二氢-吲哚类化合物 |
-
2015
- 2015-06-23 BR BR112016026596A patent/BR112016026596A2/pt active Search and Examination
- 2015-06-23 CA CA2950475A patent/CA2950475C/en active Active
- 2015-06-23 SG SG11201610740QA patent/SG11201610740QA/en unknown
- 2015-06-23 AU AU2015279377A patent/AU2015279377B2/en not_active Ceased
- 2015-06-23 WO PCT/EP2015/064016 patent/WO2015197567A1/en active Application Filing
- 2015-06-23 PE PE2016002205A patent/PE20161476A1/es unknown
- 2015-06-23 CN CN201580031351.1A patent/CN106459029B/zh active Active
- 2015-06-23 EA EA201692558A patent/EA033420B1/ru not_active IP Right Cessation
- 2015-06-23 MX MX2016016383A patent/MX2016016383A/es active IP Right Grant
- 2015-06-23 CR CR20160578A patent/CR20160578A/es unknown
- 2015-06-23 JP JP2016575164A patent/JP6442537B2/ja active Active
- 2015-06-23 UA UAA201700735A patent/UA119175C2/uk unknown
- 2015-06-23 EP EP15730199.5A patent/EP3160957B1/en active Active
- 2015-06-23 KR KR1020177002270A patent/KR101819433B1/ko active IP Right Grant
- 2015-06-23 MY MYPI2016002059A patent/MY186124A/en unknown
- 2015-06-24 AR ARP150102019A patent/AR100979A1/es unknown
- 2015-06-25 TW TW104120602A patent/TWI659025B/zh not_active IP Right Cessation
-
2016
- 2016-10-27 IL IL248550A patent/IL248550B/en active IP Right Grant
- 2016-11-09 PH PH12016502231A patent/PH12016502231B1/en unknown
- 2016-12-14 CL CL2016003212A patent/CL2016003212A1/es unknown
- 2016-12-22 US US15/389,275 patent/US20170101409A1/en not_active Abandoned
-
2019
- 2019-07-19 US US16/516,443 patent/US20200010466A1/en not_active Abandoned
-
2020
- 2020-10-13 US US17/069,534 patent/US20210246133A1/en not_active Abandoned
-
2021
- 2021-04-22 US US17/238,013 patent/US20220033395A1/en not_active Abandoned
-
2023
- 2023-08-17 US US18/451,702 patent/US20230391778A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016502231A1 (en) | Indolin-2-one or pyrrolo-pyridin-2-one derivatives | |
| MX370661B (es) | Derivados de indolin-2-ona o pirrolo-piridin/pirimidin-2-ona. | |
| AR106589A1 (es) | Derivados de indolin-2-ona | |
| AR106590A1 (es) | Derivados de indolin-2-ona | |
| AR106588A1 (es) | Derivados de indolin-2-ona para el tratamiento de enfermedades del snc | |
| CR20180022A (es) | Derivados etinilo. | |
| MX2015015893A (es) | 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen. | |
| EA201590438A1 (ru) | 2-оксо-2,3-дигидроиндолы для лечения расстройств центральной нервной системы | |
| PH12016501100A1 (en) | Ethynyl-imidazolin-2, 4-dione derivatives as mglur4 modulators | |
| MX2016008842A (es) | Derivados de n-fenil-lactama capaces de estimular la neurogenesis y su uso en el tratamiento de trastornos neurologicos. | |
| EA201692488A1 (ru) | Пептиды, выполняющие роль агонистов окситоцина | |
| MX2016000895A (es) | Derivados de 1,7-naftiridina. | |
| EA201691831A1 (ru) | Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов | |
| AR106591A1 (es) | Derivados de indolin-2-ona | |
| MX2015015052A (es) | Derivados de isoquinolina que estimulan la neurogenesis. | |
| EA201691788A1 (ru) | Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов | |
| PH12016502232A1 (en) | Peptides as oxytocin agonists | |
| MX2016013412A (es) | Derivados de morfolina-piridina. | |
| EA201690971A1 (ru) | ПИРИДО[4,3-b]ПИРАЗИН-2-КАРБОКСАМИДЫ В КАЧЕСТВЕ НЕЙРОГЕННЫХ СРЕДСТВ ДЛЯ ЛЕЧЕНИЯ НЕЙРОДЕГЕНЕРАТИВНЫХ РАССТРОЙСТВ | |
| MX2016014845A (es) | Derivados indolin-2-ona y 1,3-dihidro-pirrol[3,2-c]piridin-2-ona. | |
| EA201590125A1 (ru) | ПИПЕРАЗИНО[1,2-a]ИНДОЛ-1-ОНЫ И [1,4]ДИАЗЕПИНО[1,2-a]ИНОДОЛ-1-ОН | |
| EA201992055A1 (ru) | Ингибиторы бета-секретазы | |
| MX2016001528A (es) | Derivados de indol-carboxamida. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |